LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million. In the quarter to June 2026, revenue grew 9.72%, EPS fell 92.5% and free cash flow fell 229.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LENZ
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
0.01 | 19.82 | 376.98 | 268.23 | 65.79 | 209.14 | 292.35 |
Receivables |
— | — | — | — | — | — | 0.33 |
Inventory |
— | — | — | — | — | — | 2.94 |
Total current assets |
0.01 | 21.10 | 381.74 | 275.37 | 67.24 | 211.92 | 301.41 |
Property, Plant, Equpment (Net) |
— | 1.46 | 6.51 | 22.63 | 0.05 | 0.65 | 1.19 |
Long-Term Investments |
— | — | — | 15.32 | — | — | — |
Long-term assets (Other) |
— | — | 2.17 | 3.01 | 0.02 | 1.40 | 2.54 |
Total non-current assets |
— | 1.46 | 20.25 | 46.54 | 3.13 | 3.39 | 4.46 |
Total Assets |
0.01 | 22.56 | 401.99 | 321.90 | 70.38 | 215.30 | 305.88 |
Accounts Payable |
— | 0.63 | 2.45 | 2.61 | 5.71 | 4.26 | 4.17 |
Accrued Expenses |
0.02 | 2.36 | 4.21 | 6.39 | 12.80 | 6.15 | 17.02 |
Current Part of Debt |
2.21 | — | — | — | — | — | — |
Other current liabilities |
0.02 | 29.06 | — | — | — | — | — |
Total current liabilities |
2.22 | 32.05 | 12.14 | 13.04 | 18.51 | 10.41 | 21.19 |
Liabilities (Preferred Stock) |
— | 55.61 | — | — | 143.39 | — | — |
Non-current Liabilities (Other) |
— | 0.32 | — | 10.82 | 0.99 | — | — |
Total non-current liabilities |
— | 55.92 | 5.79 | 12.57 | 144.57 | 0.81 | 0.35 |
Total liabilities |
2.22 | 87.97 | 17.94 | 25.61 | 163.09 | 11.22 | 21.54 |
Additional Paid In Capital |
— | 5.18 | 525.40 | 539.74 | 2.52 | 348.90 | 511.24 |
Common Stock (Net) |
— | — | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Retained Earnings |
(2.22) | (70.59) | (141.35) | (242.40) | (95.24) | (145.01) | (227.14) |
Common Equity (Total) |
(2.22) | (65.41) | 384.05 | 296.29 | (92.71) | 204.08 | 284.34 |
Shareholders Equity (Total) |
(2.22) | (65.41) | 384.05 | 296.29 | (92.71) | 204.08 | 284.34 |
Shareholders Equity and Liabilities (Total) |
0.01 | 22.56 | 401.99 | 321.90 | 70.38 | 215.30 | 305.88 |
Shares (Common) |
— | 1.47 | 8.29 | 8.32 | 1.97 | 27.52 | 31.35 |
Shareholders Equity (Tangible) |
(2.22) | (65.41) | 384.05 | 296.29 | (92.71) | 204.08 | 284.34 |
Net Debt |
2.20 | (19.82) | (376.98) | (268.23) | (65.79) | (209.14) | (292.35) |
Total Debt |
2.21 | — | — | 4.05 | — | — | — |